Bicycle Therapeutics PLC BCYC
Biotechnology: Pharmaceutical Preparations · IPO 2019 · data as of November 13, 2026
Bicycle Therapeutics PLC (BCYC) is a healthcare company listed in the US with a market value of about $236M. In the twelve months to September 30, 2026 it had revenue of $84M and net income of -$142M, a net margin of -169.8%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 48% a year, a 5-year average ROIC of -29%.
About Bicycle Therapeutics
Bicycle Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2019. Revenue went from $2M in 2017 to $73M in 2025, growth of about 56.1% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 134% over three years (dilution for shareholders). It spends 331% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $84M | $73M | $35M | $27M | $14M | $12M | $10M | $14M | $7M | $2M |
| Net income | -$142M | -$219M | -$169M | -$181M | -$113M | -$67M | -$51M | -$31M | -$22M | -$16M |
| Free cash flow | -$177M | -$252M | -$166M | -$64M | -$105M | -$17M | -$19M | -$30M | -$27M | -$3M |
| EPS (diluted) | $-2.03 | $-3.16 | $-2.90 | $-5.08 | $-3.80 | $-2.67 | $-2.66 | $-2.77 | $-49.78 | $-48.81 |
| Net margin | -169.8% | -301.7% | -479.2% | -669.7% | -779.4% | -571.2% | -491.0% | -221.8% | -306.1% | -789.3% |
| ROIC | — | -31.1% | -25.4% | -36.1% | -36.5% | -16.4% | -46.1% | -27.4% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $9.17, 172% above the current price; targets range from $5.00 to $14.00; the consensus rating is “Buy”; expected EPS is $-2.26 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Bicycle Therapeutics pay a dividend?
Not currently.
Is Bicycle Therapeutics a good stock to buy?
We do not give buy or sell advice. Bicycle Therapeutics scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.